The Venus-PowerX TAVR valve. Graphic courtesy of Zhao et al. and The American Journal of Cardiology.
Researchers detailed their experience performing the very first TAVR procedures with the Venus-PowerX TAVR valve from Venus MedTech. The valve includes a wire-controlled mechanism that makes it possible to recapture after full deployment.
Sending helpful alerts through email and the electronic health record can make a significant impact on patient care, according to new data presented at ACC.25 and published in Circulation.
Care teams throughout the U.S. and U.K. are now exploring the safety and effectiveness of using Shockwave Medical's new Javelin IVL catheters to treat challenging, difficult-to-cross coronary lesions.
As TAVR continues to grow in popularity, researchers noted, it becomes more and more important to know how different complications impact long-term outcomes.
The TriClip T-TEER device. Image courtesy of Abbott.
CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Christopher M. Kramer, MD, during an ACC.25 press conference. Photo by Dave Fornell.
Christopher M. Kramer, MD, is a longtime cardiologist and cardiac imaging specialist. His one-year term as the head of the American College of Cardiology officially began at the end of ACC.25 in Chicago.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
